Paratek Pharmaceuticals (PRTK) Shares Down 7.6% Following Insider Selling

Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) were down 7.6% on Thursday following insider selling activity. The company traded as low as $12.63 and last traded at $12.70. Approximately 1,072,446 shares traded hands during trading, an increase of 89% from the average daily volume of 567,931 shares. The stock had previously closed at $13.75.

Specifically, Director Robert S. Radie sold 3,000 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $42,660.00. Following the transaction, the director now owns 9,330 shares in the company, valued at approximately $132,672.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Adam Woodrow sold 14,333 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total transaction of $198,798.71. Following the transaction, the vice president now owns 62,367 shares in the company, valued at approximately $865,030.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,664 shares of company stock worth $573,226. 4.90% of the stock is currently owned by company insiders.

Several research analysts have recently commented on PRTK shares. ValuEngine lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Tuesday, January 23rd. Finally, Guggenheim started coverage on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $39.25.

The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53. The company has a market capitalization of $353.45, a P/E ratio of -3.39 and a beta of 0.27.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. The business had revenue of $0.01 million for the quarter. research analysts expect that Paratek Pharmaceuticals Inc will post -3.32 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Legal & General Group Plc boosted its holdings in Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares during the period. Wells Fargo & Company MN boosted its holdings in Paratek Pharmaceuticals by 9.7% in the 2nd quarter. Wells Fargo & Company MN now owns 17,075 shares of the specialty pharmaceutical company’s stock valued at $411,000 after purchasing an additional 1,509 shares during the period. Nationwide Fund Advisors boosted its holdings in Paratek Pharmaceuticals by 22.9% in the 2nd quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock valued at $322,000 after purchasing an additional 2,492 shares during the period. Alps Advisors Inc. boosted its holdings in Paratek Pharmaceuticals by 10.2% in the 3rd quarter. Alps Advisors Inc. now owns 27,339 shares of the specialty pharmaceutical company’s stock valued at $686,000 after purchasing an additional 2,530 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in Paratek Pharmaceuticals by 7.2% in the 2nd quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 2,800 shares during the period. 75.05% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Paratek Pharmaceuticals (PRTK) Shares Down 7.6% Following Insider Selling” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/10/paratek-pharmaceuticals-prtk-shares-down-7-6-following-insider-selling.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit